Articles tagged with Drug Studies
Researchers analyzed data from over 700 patients with kidney injury and found that glucarpidase treatment improved kidney recovery rates. Glucarpidase rapidly clears methotrexate from the blood, reducing the risk of kidney toxicity.
The study identified 105 compounds in Shenqi Fuzheng extract, with organic acids and amino acids showing higher concentrations in the bloodstream. Compounds such as Astragalosides promptly enter the bloodstream within 5 minutes after administration.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
A clinical trial showed that an antibody blocking Nogo-A protein improves motor function in patients with incomplete spinal cord injuries. The treatment led to significant improvements in voluntary muscle activation and everyday life functional independence. Further studies are needed to confirm the findings.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
Longidaza significantly reduced exertional desaturation and dyspnea, as well as improved distance walked during the six-minute walk test. The drug's effects on exercise tolerance were sustained for over 100 days after treatment.
A new investigation by BMJ raises concerns over the PLATO trial that approved ticagrelor, citing discrepancies in data reporting and patient deaths. The study calls for a reappraisal of guidelines recommending the drug's use.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat was safe but did not improve mpox resolution or pain in adults with mild to moderate clade II mpox. The study recommended stopping further enrollment due to the lack of efficacy signal.
Dana-Farber Cancer Institute researchers present promising results from two studies on systemic mastocytosis: a novel drug, bezuclastinib, shows early efficacy in treating advanced SM, while a new predictive tool distinguishes between life-threatening and less aggressive forms of the disease with high accuracy
A systematic review of 45 studies found inconsistent descriptions of psychotherapy sessions, making it difficult to replicate studies and compromise patient well-being. Researchers call for improved reporting standards to enhance the replicability, safety, and potential effectiveness of these therapies.
A phase 3 trial found that combining a second-generation BTK inhibitor, acalabrutinib, with a BCL-2 inhibitor, venetoclax, resulted in high progression-free survival rates and low toxicity. The treatment showed promise in treating chronic lymphocytic leukemia (CLL) patients.
Researchers at Tokyo University of Science have developed a new, highly selective and efficient method for synthesizing anti-cancer compounds. The innovative approach uses isopropyl magnesium bromide as a base to improve selectivity and scalability.
A review paper suggests that MDMA-assisted therapy can benefit military personnel with traumatic brain injuries, improving emotional and cognitive challenges. The drug may facilitate social connections, increased self-esteem, and neural plasticity, leading to improved treatment outcomes.
A large-scale clinical trial involving over 9,000 patients reveals that text message reminders failed to improve medication refill adherence over a year. The study included diverse representation from subgroups, including females, Hispanic ethnicity, and Spanish-speaking patients.
A clinical trial demonstrated the efficacy and tolerability of concizumab, a new drug for haemophilia patients, reducing bleeding rates. Concizumab works by blocking an anticoagulant factor, restoring the delicate balance between clotting and anti-clotting factors.
Researchers analyzed hundreds of malaria parasite genomes to identify genetic variants associated with drug resistance. The study's findings can help scientists predict antimalarial drug resistance and prioritize experimental treatments.
A new injection treatment has been found to reduce the need for further treatment by 30% compared to current steroid tablets. The treatment, benralizumab, targets specific white blood cells to reduce lung inflammation and improve symptoms.
The SONIA trial found that delaying and shortening CDK4/6 inhibitor treatment in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes while reducing toxicity and cost by €45 million per year. This innovative approach could reduce the burden on healthcare systems worldwide.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
A new study led by Weill Cornell Medicine found that tirzepatide reduced the risk of diabetes in obese and prediabetic patients by more than 90% after 176 weeks. The treatment also showed significant weight loss and improved blood sugar control.
A study estimates that approximately one-third of eligible US adults without diabetes were excluded from clinical trials supporting GLP-1 and GLP-1/GIP medications. The FDA should consider updating labeling to advise caution on generalizing these medications' safety and effectiveness to excluded populations.
Researchers at the University of Liverpool used AI to develop a personalised method for treating urinary tract infections, improving accuracy and reducing antibiotic resistance. The new approach uses real-time data to target specific bacterial infections, making antibiotics more effective.
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
A phase 2b clinical trial found that sodium oxybate, an oral medication mimicking alcohol's effects, significantly improves symptoms of patients with laryngeal dystonia who respond to alcohol. The treatment provided up to 5 hours of voice relief, with no serious adverse events.
A clinical trial testing muvalaplin, a novel oral medication, safely and effectively lowered high levels of Lp(a), a type of inherited cholesterol. The study found that muvalaplin disrupted the formation of the Lp(a) particle, acting as an effective approach to lowering Lp(a) levels.
A new study from Karolinska Institutet found that long-term use of common cardiovascular drugs is associated with a lower risk of dementia. The study, which analyzed data from over 880,000 people, shows that these medications can reduce dementia risk by 4-25%.
A promising daily tablet, infigratinib, has been shown to increase height and improve proportional limb growth in children with achondroplasia. The medication is safe and effective in treating children aged 3-11 years, offering an alternative to existing treatments.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
A nasal spray form of bumetanide has been found to reduce tissue swelling in heart failure as effectively as standard oral and intravenous formulations. This new treatment option could provide a valuable tool for treating heart failure, promoting care at home and reducing hospital admissions.
A recent study found that electronic letter reminders highlighting the cardiovascular benefits of influenza vaccines increased vaccination rates among over 2 million adults in Denmark. The strategy showed a greater impact on those who have had a heart attack, improving flu shot rates by potentially being cardioprotective. The research ...
Research found that spironolactone reduced the likelihood of heart failure after a heart attack, but did not significantly reduce deaths or other severe heart-related events. The study included over 7,000 adults in 14 countries who had experienced a severe heart attack.
A study found that 64% of clinical trials for the top 30 highest-revenue medicines had their data accessible to researchers, a significant improvement over prior assessments. Companies using independent platforms achieved higher eligibility rates than those relying on internal processes.
A randomized trial found reconditioned pacemakers comparable to new devices in terms of safety and effectiveness up to 90 days after implantation. However, longer-term follow-up is necessary to confirm the safety and efficacy of reconditioned devices.
A clinical trial found that combining two commonly recommended medications into a single pill lowered blood pressure and was safe among Indian adults. The study's results have significant meaning for South Asian adults, including those living in the US.
A large-scale clinical trial found that intravenous infusion of exenatide during heart surgeries involving bypass did not significantly reduce the risk of death, stroke, or organ failure. The study included approximately 1,400 adults and a randomized, double-blind, placebo-controlled design.
The international SUMMIT trial found tirzepatide lowered the risk of worsening heart failure events and cardiovascular death in obese adults with preserved ejection fraction. Participants experienced improved health status, physical function, and exercise tolerance compared to placebo.
A recent study published at the American Heart Association's Scientific Sessions 2024 found that blood thinners did not reduce cognitive decline in adults younger than age 65 who have atrial fibrillation (AFib) but no other risk factors for stroke. The trial included over 1,200 participants and followed them for an average of 3.7 years...
A new combination of immunotherapy and epigenetic drug may transform resistant pancreatic tumors into susceptible ones, according to a study by Johns Hopkins Medicine researchers. The treatment showed promise in a subset of patients, with tumor shrinkage and durable responses observed over several months.
New treatment combinations and predictive biomarkers hold promise for improving bladder cancer outcomes. The NIAGARA trial showed that combining immune checkpoint inhibitors with chemotherapy can significantly increase two-year survival rates and reduce cancer recurrences.
A clinical study found that an FasL inhibitor, asunercept, led to a faster recovery of COVID-19 patients in eight days compared to 13 days in the control group. The treatment also reduced mortality by about 20%. The study suggests a new therapeutic concept for severe COVID-19.
Developed by University of Copenhagen researchers, a new nanofiber patch reduces psoriasis treatment frequency to once a day, improving comfort for patients. The patch releases two active ingredients at different rates, addressing the need for multiple products in psoriasis treatment.
Research by the University of Sydney has identified CBN as a constituent that improves sleep in rats. The study showed that CBN increased both NREM and REM sleep, leading to increased total sleep time.
A large international study found that very early medication abortion is equally effective and safe as waiting for intrauterine pregnancy confirmation. The study included over 1,500 women who received two drugs – mifepristone and misoprostol – in either a delayed or early abortion group.
A study found that using an orbital atherectomy device to remove calcium from blocked coronary arteries before stenting procedures did not improve patient outcomes. The device was used on patients with moderately severe calcification, rather than extreme cases, and did not show significant benefits.
Researchers have developed a technology called FarrSight-Twin that creates digital twins of real cancer patients to predict treatment response. The approach was tested on published clinical trials and showed accurate predictions in all simulated studies, with 75% response rate among patients receiving the predicted best treatment.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers developed a nanomedicine that attacks bacteria at the molecular level, reducing antibiotic resistance and side effects. The technology releases medication only when required, ensuring patients take exact amounts to fight infections.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
Researchers at USC Dornsife discover that mifepristone increases mitophagy to the same extent as rapamycin, potentially extending lifespan. The study found that combining the two drugs does not offer additional benefits and slightly reduces lifespan, suggesting they act through the same biological pathway.
The use of GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors in people with type 1 diabetes has significantly increased between 2010 and 2023. This trend is driven by their benefits in weight management and cardiorenal protection, but caution is advised due to concerns about euglycemic diabetic ketoacidosis.
A new study found that long-term, low-dose valacyclovir treatment significantly reduces the risk of vision-damaging bouts of inflammation and infection in patients with shingles. Participants treated for a year saw a 26% reduction in eye disease flare-ups at 18 months.
A new study has found that men and women utilize different biological systems to relieve pain. Women rely on non-opioid based pathways, which may explain why they respond poorly to opioid therapies and are more likely to become addicted. The research suggests tailoring pain treatment to an individual's sex may improve patient outcomes.
Researchers at Johns Hopkins Medicine developed a potential novel treatment for breast cancer bone metastasis using RK-33, which targets and inhibits the protein DDX3. The drug successfully eliminated breast cancer bone metastases in lab models by controlling cancer cell growth and proliferation.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers have developed a peptide inhibitor called RI-AG03 that effectively prevents Tau protein aggregation in lab and fruit fly studies. The breakthrough targets both major aggregation-promoting 'hotspots' of the Tau protein, potentially paving the way for more effective treatments for neurodegenerative diseases.
Researchers have developed a promising new drug, RI-AG03, that successfully targets and blocks both major aggregation-promoting 'hotspots' of the Tau protein. The peptide-based approach shows significant potential in preventing the build-up of Tau proteins and neurodegeneration, addressing a critical gap in current treatments.
A new clinical trial reveals that synthetic cannabis, specifically dronabinol, can effectively reduce agitation in patients with Alzheimer's disease by an average of 30%. The treatment showed similar calming effects to current medications without adverse results such as delirium or seizures.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.